Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-30 17:58:59 UTC |
---|
Update Date | 2014-12-24 20:26:07 UTC |
---|
Accession Number | T3D3516 |
---|
Identification |
---|
Common Name | Itraconazole |
---|
Class | Small Molecule |
---|
Description | Itraconazole is only found in individuals that have used or taken this drug. It is one of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis. [PubChem]Itraconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. |
---|
Compound Type | - 14-alpha Demethylase Inhibitor
- Amine
- Antifungal Agent
- Antiprotozoal Agent
- Drug
- Ether
- Metabolite
- Organic Compound
- Organochloride
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | ITC | ITCZ | Itraconazol | Itraconazolum | Itrizole | ITZ | Onmel | Oriconazole | Sporal | Sporanox |
|
---|
Chemical Formula | C35H38Cl2N8O4 |
---|
Average Molecular Mass | 705.633 g/mol |
---|
Monoisotopic Mass | 704.239 g/mol |
---|
CAS Registry Number | 84625-61-6 |
---|
IUPAC Name | 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one |
---|
Traditional Name | itraconazole |
---|
SMILES | [H]C(C)(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@]2([H])CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1 |
---|
InChI Identifier | InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1 |
---|
InChI Key | InChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as phenylpiperazines. Phenylpiperazines are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazinanes |
---|
Sub Class | Piperazines |
---|
Direct Parent | Phenylpiperazines |
---|
Alternative Parents | |
---|
Substituents | - Phenylpiperazine
- N-arylpiperazine
- Phenyltriazole
- Phenyl-1,2,4-triazole
- Aminophenyl ether
- Phenol ether
- Phenoxy compound
- Tertiary aliphatic/aromatic amine
- 1,3-dichlorobenzene
- Dialkylarylamine
- Aniline or substituted anilines
- Halobenzene
- Alkyl aryl ether
- Ketal
- Chlorobenzene
- Aryl halide
- Benzenoid
- Monocyclic benzene moiety
- Aryl chloride
- Azole
- 1,2,4-triazole
- Triazole
- Meta-dioxolane
- Heteroaromatic compound
- Tertiary amine
- Ether
- Azacycle
- Oxacycle
- Acetal
- Organochloride
- Organohalogen compound
- Organooxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Amine
- Organic oxygen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 166.2°C | Boiling Point | Not Available | Solubility | Insoluble | LogP | 5.66 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-00e9-6214197000-1ee5b13e7088e9cfe8f4 | 2017-11-06 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0lz0-0594300000-f8fca354ab686af07f2d | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0lz0-0594300000-f8fca354ab686af07f2d | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0udi-0329000000-18fc35342fd0b509b439 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0a4i-0112100900-c45b863fbc00a8c449b4 | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0a4i-2014019700-85126d2b5b6964cb167d | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-03di-4911034000-399215ad81f2268c5d61 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-00di-9132010000-ae7c2d5fe82a8f94b236 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-014i-9013020100-071002be4024d571dbb9 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-014i-9011000000-14b98a8a8e8671d57c64 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-00or-7094010000-5df5528d83df0744427a | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0udi-1000002900-92f9c0efb49798e3bcf6 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0ufr-2020019400-0234895cdc4dcdafd7ad | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0uyl-5284109100-cbdacae0a2b5183f54c6 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0a4i-0000001900-c0509f1b5423bc42d985 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0a4i-0000037900-6204ee9c5fe37a35c4f4 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-00di-9040343100-71b0ddcafedcd83a768c | 2021-10-11 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal. |
---|
Mechanism of Toxicity | Itraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. |
---|
Metabolism | Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.
Route of Elimination: Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.
Half Life: 21 hours |
---|
Toxicity Values | No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg. |
---|
Lethal Dose | No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg. (1) |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB01167 |
---|
HMDB ID | HMDB15298 |
---|
PubChem Compound ID | 55283 |
---|
ChEMBL ID | CHEMBL22587 |
---|
ChemSpider ID | 49927 |
---|
KEGG ID | Not Available |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 6076 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Itraconazole |
---|
PDB ID | 1YN |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Itraconazole |
---|
References |
---|
Synthesis Reference | Jong-Soo Woo, Hong-Gi Yi, “Antifungal oral composition containing itraconazole and process for preparing same.” U.S. Patent US6039981, issued May, 1998. |
---|
MSDS | Link |
---|
General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|
Down-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|